Federal judge rules in favor of Sanofi, Regeneron in patent suit over cholesterol drugs
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha.
Amgen drops price of cholesterol-lowering drug Repatha by 60 percent
Equity research analysts wrote in a note Thursday that the move could have a beneficial read-across to another drug that has the same target as Repatha.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.